Qnovia develops a novel inhaled drug delivery platform designed to effectively administer a wide range of pharmaceuticals. This proprietary technology optimizes dosing, increases therapeutic efficacy, and improves patient adherence compared to traditional delivery systems. The platform aims to enhance existing drug therapies and facilitate the delivery of new inhaled treatments for widespread health applications.
Funding
$43.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current smoking cessation therapies often suffer from poor patient compliance and suboptimal drug delivery, contributing to the persistent global smoking epidemic and its associated high mortality rates. Traditional pharmaceutical drug delivery systems have limitations in optimizing dosing and ensuring consistent efficacy, hindering successful smoking cessation.
Solution
Qnovia has developed a proprietary inhalation-based drug delivery platform designed to improve the efficacy and compliance of pharmaceutical treatments, initially targeting smoking cessation. The platform optimizes drug dosing and provides tracking capabilities to ensure consistent and effective delivery. By addressing the limitations of traditional drug delivery systems, Qnovia aims to improve patient outcomes and reduce the number of deaths caused by tobacco use. The technology is designed as a versatile platform with the potential to deliver a variety of inhaled therapies beyond smoking cessation.
Target Audience
The primary target audience includes individuals seeking effective smoking cessation therapies, healthcare providers, and pharmaceutical companies looking to improve drug delivery methods.
Features
- Proprietary inhalation technology for optimized drug delivery.
- Precise dosing and tracking capabilities to enhance treatment efficacy.
- Designed to improve patient compliance with pharmaceutical regimens.
- Potential for application across a broad range of inhaled therapies.